211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
Conditions: Acute Lymphoblastic Leukemia in Remission; Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Acute Myeloid Leukemia in Remission; CD45-Positive Neoplastic Cells Present; Chronic Myelomonocytic Leukemia; Myelodysplastic Syndrome With Excess Bla sts; Recurrent Adult Acute Myeloid Leukemia; Refractory Adult Acute Lymphoblastic Leukemia Interventions: Drug: Cyclosporine; Drug: Fludarabine Phosphate; Other: Laboratory Biomarker Analysis; Drug: Mycophenolate Mofetil; Procedure: Peripheral Blood Stem Cell Transplantation; Other: Pharmacological Study; Radiation: Pretargeted Radioimmunotherapy; Drug: Sirolimus; Radiation: Total-Body Irradiation Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI) Not yet recruiting - verified April 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Leukemia | Myelodysplastic Syndrome | Restasis | Stem Cell Therapy | Stem Cells | Study | Transplants